CD19 or BCMA directed CAR T-cell therapies – Risk of secondary malignancy of T-cell origin
18/07/2024
Medicines for human use
Direct healthcare professional communication (DHPC)
Important Safety Information from Bristol-Myers Squibb Pharmaceuticals Limited, Janssen-Cilag International NV, Novartis Ireland on behalf of Novartis Europharm Limited and Kite Pharma EU B.V.regarding Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah(tisagenlecleucel), Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel) (CD19- or BCMA-directed CAR T-cell therapies): Risk of secondary malignancy of T-cell origin